GlassScriptPhysician profile
Ronald Brancaccio
NPI 1174578769
$10,084.82
in general payments reported to CMS, 2019-2025
34 companies · $1,729 in 2025
The $1,729 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,532 · 2020: $463 · 2021: $1,337 · 2022: $1,874 · 2023: $1,669 · 2024: $1,481 · 2025: $1,729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,738 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,737.77 |
| Education | $140.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,681.90 | 2019-2025 | Rinvoq, Skyrizi |
| Sun Pharmaceutical Industries INC. | $1,114.64 | 2019-2025 | Winlevi, Ilumya |
| Merz North America, INC. | $1,095.99 | 2019-2021 | |
| Leo Pharma INC. | $753.48 | 2019-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $603.23 | 2020-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $579.71 | 2021-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $566.21 | 2022-2024 | Vtama |
| Pfizer INC. | $518.59 | 2019-2025 | |
| Amgen INC. | $461.68 | 2022-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $440.04 | 2020-2025 | |
| Genzyme Corporation | $388.68 | 2019-2025 | |
| Incyte Corporation | $325.61 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $281.36 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $175.19 | 2019-2025 | Taltz, Ebglyss |
| Galderma Laboratories, L.P. | $170.35 | 2019-2025 | Nemluvio |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $111.48 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $100.12 | 2022-2023 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $86.76 | 2019-2024 | Duobrii, Jublia, Arazlo |
| Allergan, INC. | $81.69 | 2019-2021 | |
| Epi Health, LLC | $67.47 | 2019-2022 | |
| Strata Skin Sciences, INC. | $63.72 | 2021-2023 | Xtrac |
| Ucb, INC. | $61.52 | 2025 | Bimzelx |
| Almirall LLC | $53.95 | 2019-2021 | |
| Celgene Corporation | $43.84 | 2019 | |
| Blueprint Medicines Corporation | $41.68 | 2023 | |
| Sandoz INC. | $37.44 | 2019-2020 | |
| Sebela Pharmaceuticals INC. | $31.18 | 2020-2022 | |
| Springworks Therapeutics, INC. | $29.08 | 2025 | Gomekli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.58 | 2024 | Cyltezo |
| Lnhc, INC | $23.36 | 2025 | Zelsuvmi |
| Dermira, INC. | $19.94 | 2019 | |
| Biofrontera INC. | $19.58 | 2021 | |
| Organon LLC | $17.67 | 2025 | |
| Merck Sharp & Dohme LLC | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Brancaccio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.